Scholarlink

Background <p>This study aimed to explore the risk factors of serious infections (SI) in patients with large-vessel vasculitis (LVV) in Japan.</p> Methods <p>This observational nested case-control study used an administrative claims database (April 2008 to July 2023) provided by Medical Data Vision Co., Ltd. Patients with Takayasu arteritis (TAK) and giant cell arteritis (GCA) were identified based on age and prescription of oral glucocorticoids (GC) or immunosuppressants following a definite diagnosis code. An SI was defined as an infection-related hospitalization. We identified a maximum of five controls for each case that were matched for sex, age, days of follow-up, and calendar year. The adjusted odds ratios (aORs) and 95% confidence intervals for the association between SI and risk factors were estimated using conditional logistic regression.</p> Results <p>Among 1,856 patients with TAK and 2,149 patients with GCA, 151 (8.1%) and 202 SI cases (9.4%) were identified from the TAK and GCA cohorts, respectively. The respiratory tract was the most frequent site of infection. Injectable GCs were significantly associated with SI. No significant increase in the aORs of tocilizumab was observed in either cohort. Significant comorbid risk factors included diabetes mellitus and malignant tumor in both cohorts; respiratory disease and renal dysfunction in the TAK cohort; and cerebral or cardiovascular disease in the GCA cohort.</p> Conclusion <p>Considering these risk factors, close monitoring, prevention, and management of SI are clinically important to prevent the occurrence of SI in patients with LVV.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk factors of serious infections in patients with large-vessel vasculitis after the approval of tocilizumab in 2017: a retrospective nested case-control study using the Japanese health insurance database

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月28日

查看全文
  • Sari Horiuchi,
  • Yukumitsu Kudo,
  • Kotaro Kawano,
  • Takahiko Sugihara,
  • Yoshikazu Nakaoka,
  • Ryoko Sakai,
  • Manabu Akazawa

摘要

Background

This study aimed to explore the risk factors of serious infections (SI) in patients with large-vessel vasculitis (LVV) in Japan.

Methods

This observational nested case-control study used an administrative claims database (April 2008 to July 2023) provided by Medical Data Vision Co., Ltd. Patients with Takayasu arteritis (TAK) and giant cell arteritis (GCA) were identified based on age and prescription of oral glucocorticoids (GC) or immunosuppressants following a definite diagnosis code. An SI was defined as an infection-related hospitalization. We identified a maximum of five controls for each case that were matched for sex, age, days of follow-up, and calendar year. The adjusted odds ratios (aORs) and 95% confidence intervals for the association between SI and risk factors were estimated using conditional logistic regression.

Results

Among 1,856 patients with TAK and 2,149 patients with GCA, 151 (8.1%) and 202 SI cases (9.4%) were identified from the TAK and GCA cohorts, respectively. The respiratory tract was the most frequent site of infection. Injectable GCs were significantly associated with SI. No significant increase in the aORs of tocilizumab was observed in either cohort. Significant comorbid risk factors included diabetes mellitus and malignant tumor in both cohorts; respiratory disease and renal dysfunction in the TAK cohort; and cerebral or cardiovascular disease in the GCA cohort.

Conclusion

Considering these risk factors, close monitoring, prevention, and management of SI are clinically important to prevent the occurrence of SI in patients with LVV.